8-K: Personalis Reports Surging Clinical Volume, Medicare Win

Personalis, Inc. announced preliminary Q4 and full-year 2025 results, highlighting a significant surge in clinical test volume and pivotal Medicare coverage for breast cancer surveillance.

Summary

• Preliminary total revenue for the full year ended December 31, 2025, is expected to be in the range of $69.0 million to $70.0 million, compared to $84.6 million in 2024.
• Preliminary total revenue for the fourth quarter of 2025 is expected to be in the range of $17.0 million to $18.0 million.
• Clinical test volume for the full year 2025 reached approximately 16,233 tests, a nearly 400% increase over the 3,285 tests delivered in 2024, exceeding internal growth targets by over 20%.
• Clinical test volume in the fourth quarter of 2025 was 6,183 tests, representing a 41% sequential increase over the third quarter of 2025.
• Clinical test revenue for the full year 2025 reached approximately $2.0 million, more than doubling the $0.8 million reported in 2024.
• Preliminary clinical test revenue for the fourth quarter of 2025 was approximately $0.9 million, compared with $0.2 million in the prior year period.
• Core revenue streams (Pharma tests, services, and other customers) contributed approximately $49.0 million to $50.0 million for the full year 2025 and $11.6 million to $12.6 million for Q4 2025.
• Revenue from enterprise sales (Natera) and population sequencing (VA MVP) totaled approximately $18.0 million for the full year 2025 and $4.5 million for Q4 2025.
• The company ended the year with a strong cash position of approximately $240.0 million in cash, cash equivalents, and short-term investments.
• This cash position includes approximately $109.0 million in net proceeds from the company's At-The-Market (ATM) sales program, executed at a weighted-average price of $8.43 per share.
• Personalis secured Medicare coverage approval for the surveillance of cancer recurrence in breast cancer patients.
• Landmark TRACERx data on non-small cell lung cancer (NSCLC) and VHIO data on ctDNA dynamics across solid tumors were published, reinforcing the clinical validity of the NeXT Personal platform.

Sentiment

Score: 8

Explanation: While total revenue saw a year-over-year decline, the significant growth in clinical test volume, doubling of clinical test revenue, and securing pivotal Medicare coverage for a key indication are strong positive indicators for future growth and market penetration in a high-growth segment. The robust cash position further supports strategic expansion and execution of the 'Win-in-MRD' strategy.

Positives

• Clinical test volume surged 41% sequentially in Q4 2025 to 6,183 tests, demonstrating accelerating adoption.
• Full year 2025 clinical test volume of 16,233 tests represents a nearly 400% increase over 2024 and exceeded internal growth targets by more than 20%.
• Clinical test revenue more than doubled in 2025 to approximately $2.0 million, indicating strong growth in a key strategic area.
• Secured pivotal Medicare coverage for breast cancer surveillance, which is a key catalyst for clinical revenue and market share growth in the MRD space.
• Maintained a strong cash position of approximately $240.0 million, providing ample capital for commercial expansion.
• Successfully executed an At-The-Market (ATM) sales program, raising approximately $109.0 million in net proceeds.
• Published landmark TRACERx data in Cell and VHIO data in Clinical Cancer Research, reinforcing the clinical validity and importance of the ultrasensitive MRD approach.

Negatives

• Total revenue for the full year 2025 is expected to be in the range of $69.0 million to $70.0 million, a decrease from $84.6 million reported in 2024.

Risks

• The timing and pace of new orders from customers, including ModernaTX, Inc., Merck Sharp & Dohme LLC, other biopharma customers, and VA MVP, may fluctuate.
• The success of clinical sales teams and Tempus AI, Inc.'s sales and marketing efforts is crucial for continued growth.
• The timing of tissue, blood, and other specimen sample receipts from customers can materially impact revenue quarter-over-quarter and year-over-year.
• The ability to demonstrate attributes, advantages, or clinical validity of the NeXT platform, including the NeXT Personal MRD assay remaining unique in its ultrasensitive detection, is essential.
• Future clinical data may differ from previously presented or expected results.
• The rate of adoption and use of the NeXT platform, including maintaining the accelerated adoption rates experienced in 2025, is uncertain.
• The ability to obtain Medicare coverage and reimbursement in additional indications and the timing thereof poses a risk.
• The business is subject to the impact of competition and macroeconomic factors.
• Partnering and/or collaboration arrangements may not be successful or may terminate, which could adversely impact the business or its ability to develop and commercialize services and products.
• The company has a limited number of suppliers, which could pose supply chain risks.
• Customer concentration could lead to significant revenue fluctuations if a major customer reduces orders.
• The company may opportunistically raise additional capital through equity offerings, debt financings, collaborations, or licensing arrangements, which could dilute existing shareholders.

Future Outlook

The company expects the pivotal Medicare coverage for breast cancer surveillance to act as a key catalyst for continued clinical revenue and market share growth in the MRD space. With a fortified balance sheet, Personalis plans to expand its sales footprint, secure reimbursement coverage for additional indications, and continue executing its 'Win-in-MRD' strategy in 2026. They anticipate continued demand from oncologists for their ultrasensitive MRD testing.

Management Comments

• "Personalis championed a defining year in 2025 demonstrating that our Win-in-MRD strategy is working." Chris Hall, Chief Executive Officer and President.
• "While we entered the year with an an ambitious goal to grow clinical volumes by 30% to 40% sequentially through the year, we ultimately surpassed those targets with nearly 400% clinical volume growth over last year." Chris Hall, Chief Executive Officer and President.
• "This exponential growth, culminating in over 16,000 tests, proves that oncologists are increasingly demanding the ultrasensitivity that NeXT Personal has pioneered." Chris Hall, Chief Executive Officer and President.
• "Securing Medicare coverage for breast cancer surveillance in the fourth quarter was a pivotal milestone that transforms our commercial trajectory." Chris Hall, Chief Executive Officer and President.
• "With a fortified balance sheet of ~$240 million of cash, we enter 2026 with the capital and the clinical evidence required to expand our sales footprint, secure reimbursement coverage for additional indications, and continue to execute on our Win-in-MRD strategy." Chris Hall, Chief Executive Officer and President.

Industry Context

This announcement highlights the increasing adoption and reimbursement for advanced genomic diagnostics in precision oncology, particularly in the minimal residual disease (MRD) testing segment. The securing of Medicare coverage for breast cancer surveillance is a significant development, indicating growing recognition of the clinical utility and economic value of ultrasensitive MRD technologies. The published clinical data further reinforces the company's position in a competitive and rapidly evolving market for personalized cancer management.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong clinical volume growth, pivotal Medicare coverage, and a fortified balance sheet supporting future expansion, despite a year-over-year decline in overall revenue.
• Customers (Oncologists/Patients): Enhanced access to ultrasensitive MRD testing, particularly for breast cancer patients, due to Medicare coverage. Validation through published data reinforces trust in the NeXT Personal platform.
• Employees: Positive outlook for growth and expansion, potentially leading to increased opportunities within the company.
• Creditors: Strong cash position of approximately $240 million indicates good liquidity and ability to meet short-term obligations.

Next Steps

• Expand sales footprint in 2026.
• Secure reimbursement coverage for additional indications.
• Continue to execute on the 'Win-in-MRD' strategy.
• Complete normal quarter and year-end accounting procedures and external audit by the company's independent registered public accounting firm.

Key Dates

Recommendation

Despite a year-over-year decline in total revenue, the company's strategic shift towards clinical MRD testing is showing strong positive momentum. The nearly 400% increase in clinical test volume, doubling of clinical revenue, and the pivotal Medicare coverage for breast cancer surveillance are significant catalysts for future growth and market penetration. The robust cash position of $240 million provides ample runway for commercial expansion and securing additional reimbursement. These factors suggest a strong growth trajectory in a high-value segment of precision oncology, making it an attractive investment for long-term growth.

Keywords

genomics, precision oncology, MRD testing, minimal residual disease, cancer surveillance, breast cancer, clinical diagnostics, Personalis, PSNL, NeXT Personal, Medicare coverage, financial results, Q4 2025, full year 2025